M&A / Deals Novo Nordisk partners OpenAI on R&D “transformation” PharmaphorumSeeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.M&A / DealsRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Seeking an R D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Travere Therapeutics gains FDA approval for sparsentan in FSGSNext: Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
